Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.37 |
| ▸ | GUCY1B2 | O75343 | 1/20 | 0.37 |
| ▸ | GUCY1A2 | P33402 | 1/20 | 0.37 |
| ▸ | GUCY1A1 | Q02108 | 1/20 | 0.37 |
| ▸ | GUCY1B1 | Q02153 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21612254 | 0.83 | ALDH1A1 (0.38) | ALDH1A1KDM4ECHRM2MEN1KMT2A | |
| SCHEMBL3194752 | 0.82 | ALOX5 (0.49) | ALDH1A1KDM4ECHRM2SMN1; SMN2 | |
| SCHEMBL21612251 | 0.79 | HPGD (0.55) | ALDH1A1GLAMEN1KMT2AHPGD | |
| SCHEMBL27744255 | 0.75 | ALDH1A1 (0.39) | ALDH1A1KDM4ECHRM2GLAHPGD | |
| SCHEMBL22492152 | 0.75 | MEN1 (0.41) | ALDH1A1KDM4ECHRM2MEN1KMT2A | |
| SCHEMBL19435345 | 0.74 | CLPP (0.56) | ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL17571415 | 0.74 | CLPP (0.56) | ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL31301322 | 0.73 | MEN1 (0.51) | ALDH1A1KDM4EMEN1KMT2AHPGD | |
| SCHEMBL31038153 | 0.73 | PLK1 (0.50) | ALDH1A1KDM4EHPGDSMN1; SMN2 | |
| SCHEMBL635088 | 0.73 | PLK1 (0.50) | ALDH1A1KDM4EHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020008382-A1 | PROCESS FOR PREPARATION OF ERIBULIN AND INTERMEDIATES THEREOF | DR. REDDY’S LABORATORIES LIMITED (IN) | 2020-01-09 | — | — | WO | disclosed |
| EP-2949652-B1 | Intermediates for the preparation of halichondrin B | EISAI R&D MAN CO LTD (JP) | 2019-08-07 | — | — | EP | disclosed |
| US-RE46965-E1 | Intermediates for the preparation of analogs of Halichondrin B | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-07-24 | — | — | US | disclosed |
| US-9303050-B2 | Intermediates for the preparation of analogs of Halichondrin B | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-04-05 | — | — | US | disclosed |
| EP-2949652-A1 | Intermediates for the preparation of halichondrin B | Eisai R&D Management Co., Ltd. (JP) | 2015-12-02 | — | — | EP | disclosed |
| US-20150232490-A1 | INTERMEDIATES FOR THE PREPARATION OF ANALOGS OF HALICHONDRIN B | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-08-20 | — | — | US | disclosed |
| EP-2522663-B1 | Intermediates for the preparation of halichondrin B | EISAI R&D MAN CO LTD (JP) | 2015-04-01 | — | — | EP | disclosed |
| US-8975422-B2 | Intermediates for the preparation of analogs of halichondrin B | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-03-10 | — | — | US | disclosed |
| US-RE45324-E1 | Intermediates for the preparation of analogs of halichondrin B | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-01-06 | — | — | US | disclosed |
| US-8884031-B2 | Intermediates for the preparation of analogs of halichondrin B | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-11-11 | — | — | US | disclosed |
| US-20140221635-A1 | INTERMEDIATES FOR THE PREPARATION OF ANALOGS OF HALICHONDRIN B | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-08-07 | — | — | US | disclosed |
| US-20140163242-A1 | INTERMEDIATES FOR THE PREPARATION OF ANALOGS OF HALICHONDRIN B | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-06-12 | — | — | US | disclosed |
| US-20130237711-A1 | INTERMEDIATES FOR THE PREPARATION OF ANALOGS OF HALICHONDRIN B | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-09-12 | — | — | US | disclosed |
| US-8445701-B2 | Intermediates for the preparation of analogs of halichondrin B | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-05-21 | — | — | US | disclosed |
| US-20120309988-A1 | INTERMEDIATES FOR THE PREPARATION OF ANALOGS OF HALICHONDRIN B | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-12-06 | — | — | US | disclosed |
| EP-2522663-A1 | Intermediates for the preparation of halichondrin B | Eisai R&D Management Co., Ltd. (JP) | 2012-11-14 | — | — | EP | disclosed |
| US-20120029213-A1 | INTERMEDIATES FOR THE PREPARATION OF ANALOGS OF HALICHONDRIN B | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-02-02 | — | — | US | disclosed |
| US-7982060-B2 | Intermediates for the preparation of analogs of Halichondrin B | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-07-19 | — | — | US | disclosed |
| US-20070244187-A1 | Intermediates for the Preparation of Halichondrin B | EISAI CO., LTD (JP) | 2007-10-18 | — | — | US | disclosed |
| US-20070244187-A1 | Intermediates for the Preparation of Halichondrin B | EISAI CO., LTD (JP) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244187-A1 | Intermediates for the Preparation of Halichondrin B | CDK4, CCNB1, CDK14 | CNR1 3459/4885CHRM1 4881/4885ALDH1A1 1657/4885 |
| US-20130237711-A1 | INTERMEDIATES FOR THE PREPARATION OF ANALOGS OF HALICHONDRIN B | DHPS, BMP2, CDK11B | CNR1 3579/4885CHRM1 4876/4885ALDH1A1 2475/4885 |
| US-20140221635-A1 | INTERMEDIATES FOR THE PREPARATION OF ANALOGS OF HALICHONDRIN B | ACVR1B, ACVR2B, BMP2 | CNR1 3906/4885CHRM1 4880/4885ALDH1A1 1912/4885 |
| US-20120029213-A1 | INTERMEDIATES FOR THE PREPARATION OF ANALOGS OF HALICHONDRIN B | DHPS, BMP2, CDK11B | CNR1 3579/4885CHRM1 4876/4885ALDH1A1 2475/4885 |
| US-20120309988-A1 | INTERMEDIATES FOR THE PREPARATION OF ANALOGS OF HALICHONDRIN B | ACVR1B, ACVR2B, BMP2 | CNR1 3906/4885CHRM1 4880/4885ALDH1A1 1912/4885 |
| US-20150232490-A1 | INTERMEDIATES FOR THE PREPARATION OF ANALOGS OF HALICHONDRIN B | DHPS, BMP2, CDK11B | CNR1 3579/4885CHRM1 4876/4885ALDH1A1 2475/4885 |
| US-20140163242-A1 | INTERMEDIATES FOR THE PREPARATION OF ANALOGS OF HALICHONDRIN B | DHPS, BMP2, CDK11B | CNR1 3579/4885CHRM1 4876/4885ALDH1A1 2475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.